Experts reveal one item you should never wear at the gym
But according to jewellers, fitness professionals, and medical experts, there's one item you should always remove before hitting the weights: your wedding or engagement ring.
While it might feel unnatural to leave it at home, keeping it on could cause issues like bacteria build-up, injury, or damage to your ring.
The impact to your ring
Makayla Donovan, co-founder of TMC Fine Jewellers, emphasised the importance of removing your ring at the gym, even if it's sentimental.
'Lifting weights, using resistance equipment, or even doing high-intensity movements can put unnecessary stress on your ring,' she told news.com.au.
'Over time, this can lead to misshaping, scratching, or loosening of stones. It's just not worth the risk, especially with precious metals like gold, which are softer and prone to bending or marking under pressure.'
Sweat, dirt, and bacteria that build up at the gym can also dull the ring's finish over time.
'It's something many people overlook, but grime can easily accumulate and go unnoticed, particularly with rings featuring intricate settings,' she said.
It could affect your workout
Ben Lucas, co-founder of Flow Athletic, agrees and points out that it could have consequences for your workout as well.
If a ring spins around on your finger, it can become uncomfortable during certain exercises, he explained.
'This sometimes happens when you're in a plank position, such as plank dumbbell rows or during yoga,' he said.
'You might also cut your hand if you're unlucky, and get blisters from pinching or circulation issues too.'
The potential health risks
Following this, Dr Zac, a leading GP, warns that wearing your ring at the gym could land you in the ER.
'When you're lifting weights, gripping bars, or doing high-intensity workouts, your ring acts like a friction device,' he said. 'Constant rubbing between your ring and sweaty skin can cause ring rash (also called wedding ring dermatitis).'
This is a type of contact dermatitis often triggered by trapped moisture, friction, and dead skin build-up.
And if you're not yet convinced, it gets even more alarming.
Studies have shown that rings can harbour up to 730 million bacteria, including dangerous strains like Staphylococcus aureus.
That's the same bug that causes golden staph infections, some of which are antibiotic-resistant and can be life-threatening.
'If you happen to get a micro-tear in your skin, which is common during workouts, it could be the perfect entry point for infection,' he added.
There's also the risk of allergic reactions to metals, especially if your ring is made from nickel or low-quality alloys.
And if you're still unconvinced, Dr Zac suggests Googling 'ring avulsion injury' at your own risk.
'It's when the ring gets caught on gym equipment or a weight and rips off the skin or even degloves the finger,' he warned.
So, what should you do instead?
All the experts recommend leaving your wedding ring at home or in a safe place during your workout.
If sentimentality matters, consider a silicone band, which is lightweight, hypo-allergenic, and designed to break away safely under pressure.
If you really can't bear to take it off, training gloves provide some protection, but the safest option is to leave your rings at home.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
3 hours ago
- News.com.au
Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
Today's news is all sweet on trial progress, revenue and cash Amplia to raise capital after runaway share performance Tryptamine starts binge eating 'magic mushie' trial Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased in chocolate and coconut – occasionally interspersed with a jam layer. Hold the cream and pink jelly though – it just doesn't work. Like so many drug discoveries, the lamington had serendipitous origins. The story goes that one of Queensland governor Lord Lamington's maids was serving up a yellow sponge, but accidentally dunked it into molten chocolate. Lord Lammo recommended the squares to be rolled into coconut shavings for ease of eating – and the rest is history. As is this non-sequitur. Now onto the biotech news. Lumos glows after last week's mega deal Point-of-care diagnostics house Lumos Diagnostics (ASX:LDX) reports revenue of $12.4 million for the year to June 30, up 12%. June quarter revenue declined 26% to $2.6 million, owing to the end of the US flu season. Lumos reported cash outflows of US$1.7 million for the quarter, taking June 30 cash to US$2 million. Investor interest has focused on last week's mega US distribution deal with Phase Scientific, which could deliver Lumos up to US$317 million ( $487 million) over six years. This pertains to the company's bacterial-versus-viral rapid lateral flow test, Febridx. Lumos has also signed a term sheet for a $5 million loan facility, proffered by shareholders Tenmile Ventures (Andrew Forrest) and Ryder Capital. At its discretion, Lumos can draw down the facility over the next 12 months. Cleo eyes FDA approval for ovarian cancer assay Still on diagnostics, Cleo Diagnostics (ASX:COV) says it aims to submit a US Food & Drug Administration (FDA) marketing approval application for its ovarian cancer assay next year. The company is on track to complete a supportive US trial in the December quarter. Thanks to government grants and tax incentives, Cleo reported cash inflows of $38,000, taking end of quarter cash to $6.46 million. Turning to drug development, genetic disease specialist PYC Therapeutics (ASX:PYC) reports cash outflows of $17.6 million. At quarter's end the company still had cash of $153 million. The company has dosed the first patient in a combined phase 1a/2b trial for polycystic kidney disease. PYC has achieved 'alignment' with the FDA on the structure of a registrational trial for its lead program, the blinding eye disease retinitis pigmentosa type 11. The company believes the regulator will require only a phase II trial. Tryptamine BEDS down eating disorder trial Psychedelic medicines house Tryptamine Therapeutics (ASX:TYP) has started recruiting patients for a world-first binge eating disorder (BED) study. In the open-label trial, 12 patients will be administered intravenously infused psilocybin, combined with psychotherapy. Melbourne's Swinburne University is undertaking the study, with first dosing this quarter and top line results due by the end of the year. BED is the most common eating disorder in the US and second most prevalent in Australia here. The condition can result in depression, anxiety, post-traumatic stress disorder and compulsive behaviour. Amplia passes the hat Meanwhile Amplia (ASX:ATX) shares this morning entered trading halt, ahead of a share placement and share purchase plan. Amplia thus continues the rich tradition of companies leveraging clinical trial results, in this case its stunning data for hard-to-treat pancreatic disease. Amplia has reported 17 'partial response' rates in it Accent trial, in 17 out of 55 advanced disease patients. A confirmed partial response is tumour shrinkage of more than 30%, sustained for two or more months with no new cancerous lesions detected. Amplia is testing AMP-945 (narmafotinib). AMP-945 appears to inhibit the protein FAK, which is overexpressed in pancreatic cancers. Amplia shares have surged 376% in the past 12 months, but investors still value the company at a modest $110 million. As of the end of March, Amplia had cash of $10.8 million. 'Perplexed' Imugene laments soft-as-a-sponge share price Imugene (ASX:IMU) chairman Paul Hopper hopes the company's lamington-soft share price will 'do an Amplia' (our words) and reflect the company's progress with its multiple cancer trials. The company last Monday announced its phase 1b study for an aggressive blood cancer had resulted in two additional 'complete responses' (that is, the tumours disappeared). Imugene is trialing Azer-cel, its allogeneic Car-T drug made from healthy donor T-cells rather than the patient's. Naturally, Imugene announced a $22.5 million and share purchase plan for up to $15 million. On reinstatement, the shares lost 4.5 cents, or 10%, taking the loss over the past year to around 80%. This allows for a one for 34 share consolidation. 'We are very disappointed with the share price performance,' Hopper says. 'We are perplexed why we had such a lukewarm reception to the earlier data at the start of year.' Cashed up for pivotal trial But with the share raising in train, Imugene investors should no longer fear that such a dilutionary event is around the corner. Post raising Imugene should have cash of $64 million, with management costing a 60-80 patient pivotal trial at $30-40 million. If approved, Azer-cel would be the first commercial allogenic Car-T treatment, enabling mass produced, off-the-shelf therapies. 'We are in active discussions with partners on the strategy for developing the drug and getting it approved,' Hopper says. Shares settle in orbit after last week's Meso-blast off Mesoblast (ASX:MSB) shares have taken a breather after Friday's 35% surge on the back of initial US sales of its first US-approved stem cell product. The company reported unaudited June quarter revenue of US$13.2 million ($20.3 million) for Ryoncil, its treatment for childhood graft-versus-host disease. The FDA approved Ryoncil in December last year. Mesoblast founder and CEO Prof Silviu Itescu points to higher sales in the current quarter, given US Centres for Medicare and Medicaid Services coverage became effective on July 1. The company has signed up more than 25 transplant centres and hopes to enlist all 45 priority centres by October. Bell Potter analyst John Hester says the sales were in line with the firm's expectations. 'The figure is inclusive of sales to the distributor, nevertheless it represents a reasonable proxy for hospital demand.' The firm values Mesoblast at $3.50 a share, implying 55% of upside.
SBS Australia
3 hours ago
- SBS Australia
Vibha wanted to honour her mother's wish to die voluntarily at home. She found help online
Disclaimer: The opinions in this podcast are general and non-binding. For specific advice, please consult your General Practitioner or health expert. LISTEN TO SBS Hindi 17/07/2025 19:51 Hindi LISTEN TO SBS Hindi 14/07/2025 19:09 Hindi
ABC News
6 hours ago
- ABC News
Disability advocates say NDIS changes disregard alternative therapy benefits
On the red dirt in the outskirts of Kalgoorlie in Western Australia, a large, dark bay horse gently nuzzles Cooper in the chest. The 16-year-old in a wide-brim cowboy hat smiles. It is a sweet moment between the two friends. Cooper remembers being sceptical when his parents first suggested equine therapy as a way to build confidence and better manage his emotions during a difficult period. But he gave it a go. And the results, he says, have been life-changing. "It helps regulate my emotions. "When you're in control of such a big animal, it makes the other big things in life seem less scary." In his first equine therapy session, Cooper bonded with a horse named Rio. "Rio's the biggest and scariest," he said. "He weighs over half a ton. "They say he has ADHD (attention deficit hyperactivity disorder), which is OK because I do too." Now, as Cooper gently brushes Rio under the dappled shade of a gum tree, both seem very serene. Cooper, who also has autism, accessed equine therapy through the National Disability Insurance Scheme (NDIS). However, that stopped in October when the federal government introduced significant changes to the NDIS to reduce costs, including no longer funding equine therapy. Peak disability advocacy bodies have told the government some of the new rules are too "medicalised" and don't consider the benefits of some alternative therapies. The feedback was part of a consultation period on the new NDIS Support rules, open for public submissions until July 27. The NDIS Support rules list what is and is not funded. You can read it here. One of the major changes is that the NDIS will no longer fund supports that are not "evidence-based" or directly linked to someone's disability. Equine therapy falls under the umbrella of animal therapies, which are activities designed for people to have a positive experience with animals. It can include things like rabbit petting, playing with puppies or horse riding. Often, the goal is to help people cope with or recover from mental and physical health conditions, but it can vary. Under the changes, animal therapy has been deemed an "alternative" or "complementary therapy" and now falls in the same excluded category as tarot card reading, aromatherapy and crystal therapy. Assistance animals, like guide dogs, that are specially trained to help someone manage a disability, remain funded. As does animal-assisted therapy, which is where an accredited therapist uses an animal to help clients engage in therapy and get the most out of their sessions. Music and art therapy also remain funded by the NDIS, as long as the therapists are registered with the relevant peak bodies, which require them to have undergone recognised training and accreditation. In May, the government held online consultation sessions with disability peak bodies around the NDIS Support rules. A summary document of the feedback says there is evidence some supports no longer funded by the NDIS, like (alternative) therapies, work well for people with disability, where it meets their needs. "Participants particularly spoke about therapies. They said the lists are 'medicalised' and do not consider the benefit of some alternative therapies to participants." Other feedback included that remote communities need to be considered separately from metropolitan areas. "There are gaps in services in rural and remote communities that means more flexibility is needed." The Department of Social Services (DSS), which is running the consultations, says the feedback will help make decisions about what supports will and won't be funded in the future. People with Disability Australia was one of the peak advocacy organisations to contribute to the May round of consultation. Acting chief executive Megan Spindler-Smith said there were concerns the lists were too medicalised and too focused on being evidence-based. "This drive to be evidence-based is important, but what it means is that a lot of things like alternative therapies we know work in specific cases, or for some groups of people with disability, are not able to be considered," they said. Mx Spindler-Smith said the term "evidence-based" was also problematic because people with disability had historically not been allowed to take part in research, particularly clinical research. "So then that evidence doesn't necessarily link exactly to our direct lived experience." Another concern, Mx Spindler-Smith said, was the lack of consideration and flexibility for those living in non-metropolitan areas to access funded support services. "Registered therapists don't necessarily have a home base in many regional and remote areas," they said. "Which means that there are cohorts that are never going to be able to access it in the same way and therefore have been using non-registered therapists or people who can provide a similar level under supervision but cannot be seen as part of the list." Mx Spindler-Smith said it was important those in the disability community shared their views and experiences. "Right now, there is an opportunity until July 27 for you to have your say," they said. Lynette Keleher is the owner and operator of Breakthrough Equine Therapy, where Cooper does his lessons. Ms Keleher said Cooper was just one of hundreds of young people on the NDIS she had seen benefit from equine therapy over the years. She likened it to learning a new language or musical instrument in terms of how it engaged the body, brain and emotions. "We have a retainment rate of 90 per cent. Week after week, our clients return eager to see their favourite horse and reconnect. "You can see their troubles, negative thoughts and self-doubts disappear." Ms Keleher said previously, the business had about 50 per cent NDIS clients but had to pivot to offering other services when the changes came into effect. She said the financial impact meant a reduction in the number of staff — many of whom were NDIS participants employed through Breakthrough. Kalgoorlie-Boulder resident Jo Russell said her 21-year-old daughter Megan, regularly attended the equine therapy sessions at Breakthrough. "The gains she had made — it matched up with her NDIS goals. It aligned with what we were trying to develop and create for her and with that little stroke of the pen … it's all gone." Megan Russell requires full-time care. She is non-verbal, has autism, an intellectual disability and hip dysplasia. Her mother, Jo Russell, said the equine therapy sessions had both psychosocial and physical benefits. The physical benefits came from sitting up straight in the saddle and riding, which improved her daughter's mobility, posture and flexibility. And the psychosocial benefits, Ms Russell said, came from feeding and grooming horses, and interacting with staff, which helped break down the interpersonal gaps that came from her autism and avoiding contact. Ms Russell said continuing with the sessions, without the support of the NDIS, was not financially feasible. "[My daughter] is on a disability support pension. I'm on a disability support pension. I couldn't afford it for her, she couldn't afford it for herself," Ms Russell said. Ms Russell said she had heard similar stories from other members of the Goldfield region's disability community. "They're all very distressed because some of them can see their children regressing," she said. "The gains that have been made [through equine therapy], have now been lost." Ms Russell said the changes disproportionately affected regional and remote communities, like Kalgoorlie-Boulder, which struggled to attract and retain experienced specialists and health professionals. Psychologist and animal-assisted therapy expert, Professor Pauleen Bennett, said while there could be benefits to activities like equine therapy — the term "therapy" was misleading and the lack of regulation and oversight had the potential to cause harm. Professor Bennett said the alternative could be damaging and meant people might be missing out on real therapy with a qualified therapist. "For me, the critical difference is whether it's therapy or whether it's something else," she said. "That doesn't mean we shouldn't be doing it, and maybe the NDIS needs to be looking as some sort of way of accrediting people or organisations who do animal-assisted activities, but without calling it therapy," she said. Without the proper checks and balances that existed for other allied health services, Professor Bennett said anyone could claim to provide animal therapy — and there was no way for people to know whether it was fantastic or terrible. "We need some way of ensuring that the activities that they're doing are having a positive benefit," she said. "For some people, they definitely are. But without some sort of quality control … it's difficult to know." Meanwhile, Cooper and his family will be watching the outcome of the NDIS Support rules review closely. The Kalgoorlie teenager has not stopped equine therapy sessions entirely, but without the support of NDIS funding, they say visits will be fewer and far between.
